Abpro Holdings, Inc. ABPO

ABPO Company Overview

Abpro Holdings, Inc. (NASDAQ: ABPO) is a biotechnology company focused on the discovery and development of next-generation antibody therapeutics for oncology and immunology applications. The company operates within the biopharmaceutical industry and concentrates primarily on engineered monoclonal antibodies and T-cell engager platforms intended to improve tumor targeting and immune activation. Its core revenue and enterprise value are tied to research collaborations, licensing arrangements, and the advancement of proprietary therapeutic candidates through preclinical and clinical development.

The company traces its origins to antibody engineering research centered on creating highly specific immunotherapies with potentially improved safety and efficacy profiles. Abpro evolved from a platform-based antibody discovery company into a clinical-stage biotechnology enterprise emphasizing bispecific antibody development. The company’s positioning is based on its proprietary antibody engineering capabilities and its focus on immune-oncology therapies designed to address difficult-to-treat cancers and unmet medical needs.